Tetanus toxoid and CCL3 improve DC vaccines
AssigneeDuke University
InventorsJohn H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
Life of this patent
Estimating the term…
Loading patent…
AssigneeDuke University
InventorsJohn H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
Estimating the term…
Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.
A kit comprising a container comprising a tetanus toxoid, a diphtheria toxoid and either a CMV antigen or a RNA encoding a CMV antigen.
Dependencies are inferred from the claim text.